Overview of Insulin Therapy And Glp 1 Analogues Powerpoint Presentation Free

Insulin Therapy and GLP-1 analogues An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Download presentation by click this link.

Avoid initiating people with GLP-1 during the national shortage therefore when referring new patients for injectable therapy remind them its not for GLP-1 but daily insulin therapy
PPTX PowerPoint Presentation

The fact that insulin stimulation is glucose-dependent is a primary reason why incretins are uncommonly associated with hypoglycemia when used as monotherapy, and less often associated with hypoglycemia than many other comparators when used in combination.
The Ohio State University October 11, 2022 Objectives Review pertinent information about the most common GLP-1 agonists [Trulicity, Ozempic, and Victoza] including: Mechanism of action Dosing frequency What to do if a patient misses a dose

PDF PowerPoint Presentation
Rosenstock J, et al. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
GLP-1 analogues , primarily used for diabetes management, also show promise in treating various conditions such as Alzheimer's and Parkinson's diseases, and obesity by exerting neuroprotective and metabolic effects. Additionally, these agents may mitigate cardiovascular risks and improve outcomes in patients with conditions like polycystic ovary syndrome (PCOS). Despite their therapeutic ...

PPT Glucagon
The effect of GLP-1 to augment insulin secretion leads to enhanced muscle glucose uptake and increased suppression of lipolysis in adipocytes. GLP-1 inhibits gastric emptying leading to a decline in postprandial hyperglycemia.
Glucagon-like peptide 1 ( GLP-1 ) is an incretin hormone that enhances glucose-dependent insulin secretion from pancreatic beta cells. GLP-1 levels are reduced in patients with type 2 diabetes. Therapeutic strategies that augment the GLP-1 pathway include GLP-1 receptor agonists such as exenatide and liraglutide, as well as dipeptidyl peptidase-4 (DPP-4) inhibitors which prevent the breakdown of ...

PPT Glucagon
The enhanced insulin response with incretin administration may account for the improved glucose tolerance. * GLP-1 and Exendin-4 have a high homology in their sequences. One of the key differences is that GLP-1 has an alanin residue in the penultimate position of the N-terminus. Therefore it is a substrate of DPPIV.








WHEN TO START GLP-1S -NICE GUIDELINE [NG28] : UPDATED JUNE 22 If triple therapy with metformin and 2 other oral drugs is not effective, not tolerated or contraindicated, consider triple therapy by switching one drug for a GLP-1 mimetic for adults with type 2 diabetes who: